Head & Neck

Head & Neck Squamous Cell Carcinoma (SCC):

First Line

CIRB #H-32379/ RTOG #R1216: Randomized Phase II/III Trial of Adjuvant Radiation Therapy with Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck

CIRB # H-41338/ NRG #HN006: Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer

CIRB # H-39827/ NRG #HN005: Randomized Phase II/III Trial of De-Intensified Radiation Therapy for Patients with Early-Stage, p16-Positive, Non-Smoking Associated Oropharyngeal Cancer

CIRB #H-37278/NRG #HN004: Randomized Phase II/III Trial of Radiotherapy with Concurrent MEDI4736 (Durvalumab) Vs. Radiotherapy with Concurrent Cetuximab in Patients with Stage III-IVB Head and Neck Cancer with a Contraindication to Cisplatin (temporary closure)

Second Line / Recurrent

IRB #H-38134/ RTOG Foundation #R3507 (KEYSTROKE): A Randomized phase II study of Pembrolizumab (KEYTRUDA®) plus STeReOtactic Re-Irradiation versus SBRT alone for Locoregionally Recurrent or Second Primary Head and NEcK Carcinoma

Central IRB #H-42728/ #Merck MK7902-009 (LEAP009): A Phase 2, randomized, open-label three-arm clinical study to evaluate the safety and efficacy of lenvatinib (E7080/MK-7902) in combination with pembrolizumab (MK-3475) versus standard of care chemotherapy and lenvatinib monotherapy in participants with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) that have progressed after platinum therapy and immunotherapy (PD-1/PD-L1 inhibitors) (LEAP-009) (pending)

Nasopharyngeal:

CIRB #H-33148/NRG #HN001: Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)